Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » ITEC Makes Award to RND Pharmaceuticals
Uncategorized

ITEC Makes Award to RND Pharmaceuticals

By medwebNov 1, 2005
Share
Facebook Twitter Email

November 7, 2005

Contact: Megan Fellman at (847) 491-3115 or at
fellman@northwestern.edu

ITEC Makes Award to RND Pharmaceuticals
EVANSTON, Ill.—The Illinois Technology Enterprise Center (ITEC)–Evanston at Northwestern University has invested $25,000 in RND Pharmaceuticals, Inc., a privately held biopharmaceutical company located in Palatine.

RND is dedicated to the discovery, development, and commercialization of proprietary small molecule therapeutics that address unmet medical needs. This is the sixth investment ITEC has made from its pre-seed fund for technology startup companies.

Stephen Gately, president of RND Pharmaceuticals, says that drugs now on the market for other diseases could also be useful in treating cancer. However, drawbacks such as short half-lives, insufficient potency, and toxic side effects that result when the drugs are used at higher levels often prevent their use for cancer.

Gately, an adjunct assistant professor in the Division of Hematology/Oncology in the Department of Medicine at Northwestern’s Feinberg School of Medicine, is experienced in both large pharmaceutical and high-growth biotech companies. RND chemically modifies existing compounds to improve their activity and reduce or eliminate toxicities. He recently founded RND along with co-founder Stephen Wanaski to bring these new, more effective therapeutics rapidly to cancer patients, giving them more treatment options.

ITEC–Evanston was impressed by the knowledge and experience of the founders, the respect they have from peers, and their approach to drug development. “We believe that this approach, using validated chemical techniques to modify FDA-approved compounds already known to have anticancer activity, is a great way to reduce the risk inherent in developing new drugs,” said Jeff Coney, director of ITEC–Evanston. “We think this is a fantastic high-growth opportunity, and we are excited to help the company move forward.”

RND’s lead compound with cancer-fighting ability is now in animal trials at the Center for Translational Drug Development, an affiliate of the Translational Genomics Research Institute in Phoenix. Several additional compounds are in laboratory testing. The company has filed composition of matter patents on the derivative compounds.

The ITEC program was established by the State of Illinois in 2000 to provide services relevant to the formation, growth, and retention of early-stage technology companies in Illinois. Initial funding for ITEC–Evanston was based on a $500,000 grant from the state, $150,000 and office space from Northwestern University, and $50,000 from the Northwestern University/Evanston Research Park.

Since 2002 Northwestern University has been awarded subsequent grants totaling $1.5 million by the Illinois Department of Commerce and Economic Opportunity (DCEO) to support continuation of the center and to establish a pre-seed fund for technology startups. ITEC–Evanston is actively seeking new applicants to its Pre-Seed Fund. Managed by the University, the center has served more than 200 entrepreneurs and early-stage companies since its inception.

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.